Gilead halts lung drug trial, takes another hit to once-vaunted deal February 10, 2021 San Francisco Biotechnology Network News News Comments Off on Gilead halts lung drug trial, takes another hit to once-vaunted deal Less than two years after launching the $5 billion deal, Gilead and Galapagos have registered more failures than successes from their collaboration. Click to view original post